Leah Amir, MS, MHA CEO
XCellCure CEO Leah Amir has achieved commercial success throughout her career, starting with her experience at Mallinckrodt Medical and extending through her input as Executive Director of The Institute for Quality Resource Management. She has developed and provided creative solutions to vastly increase market share for Biosphere Medical, Medtronic, Zimmer, RadioTherapeutics, DataScope, and FocalSeal in addition to many other companies. As a Partner at Data Management Consultants, she achieved exceptional growth through sales negotiation to Modis in 1999. With 20 years of experience leading commercialization of new products, Leah Amir has become an expert in delivering clinical solutions in numerous areas of medical practice including cardiovascular disease, orthopedics, diagnostics, and tissue regeneration.
Expertise: Product development, FDA submission / clearance, Reimbursement, Sales Force Training, and Implementation of routine use of new technology.
Gary Anderson, Vice President Product Development
With over two decades of experience developing and conducting novel molecular and biochemical assays to characterize human diseases at Pfizer, Gary is the technological driving force behind research and development at XCellCure. He is exceptionally adept at developing inimitable assays for the detection of circulating human biomarkers and has meticulous skill in creation, validation and verification of clinical assays.
Expertise: Highly experienced at developing unique assays to detect novel markers using human blood or non-invasively sampled bodily fluids. Gary provides meticulous evaluation of technologies to support development of the specification of the technology platform and will continue to support serial validation testing of platforms throughout the development process.
Jim Carlile, Strategic Advisor
Jim has extensive experience growing sales and launching products against competition to emerge as the market leader. As the past president at Mallinckrodt Medical Imaging Division, Jim developed a core team to drive sales of a 3rd to market diagnostic product exceeding $1 billion over a mere 3 years. Having recently participated in the successful launch of other privately-financed medical product opportunities, Jim has in-depth knowledge of the strategy necessary for financial realization in the world of medical technology.
Expertise: Executive-level management experience, board participation, hands-on comprehension of the dynamics of launching products worldwide while delivering shareholder value
Frankie obtained his PhD in Bioengineering from UC Berkeley in 2012, where he specialized in microfluidic devices for quantitative cell biology and point-of-care diagnostics. In addition to his position with XCellCure, Frankie currently teaches courses on medical instrumentation at UC Berkeley. He brings broad technical expertise to the team in microfabrication, electronics, software development, and molecular diagnostics.
Expertise: Bioengineering, Cell Biology, Point of Care Medical Technology, Microfabrication, Software Development, Molecular biology, Medical Diagnostics
Scientific Advisory Board
Biomarker Discovery Team
Stuart T. Higano, MD, FACC Stuart is on staff at Missouri Baptist Medical Center as a High Volume Interventional Cardiologist. He is board certified in internal medicine, cardiovascular diseases, nuclear cardiology and interventional cardiology and has strong ties to the Mayo Clinic in Rochester, MN. Dr. Higano completed his medical degree at the University of Massachusetts Medical School in Worcester, MA and completed all post-graduate training at the Mayo Clinic, including his residency in internal medicine, a cardiovascular training program, and an interventional cardiology fellowship
John Kirby, MD, FCCWS, FACS Surgery / General Surgery John currently practices in the Division of Acute and Critical Care Surgery Washington University School of Medicine. In addition to his employment at Washington University, John is an Associate Professor of Surgery in the Division of General Surgery - Acute and Critical Care Surgery Section and Director of the Wound Healing Program Barnes-Jewish Hospital & Washington University School of Medicine in St. Louis, Missouri. His experience in high volume institutions with immensely varied patient populations is an asset to support clinical trials in the area of emergency detection of an impending MI and for patients with acute and chronic wounds.
Robert Bolla, PhD Molecular Biologist Dr. Bolla recently served as Associate Provost for Research at Bradley University in Peoria, IL. Prior to his post at Bradley University he was Chairman of the Biology Department at St. Louis University. Bob brings to XCellCure extensive experience launching innovative technologies for SLU and later Bradley University.
Dr. Erik (E.A.L.) Biessen, PhD Dr. Biessen currently serves as a Professor of Experimental Vascular Pathology at University of Maastricht. He is the principal Investigator on multiple studies fueling the innovative technology at XCellCure including groundbreaking studies regarding the prognostic value of Cardiac Biomarkers CCL3, CCL5, and CCL18.
Dr. Theo van Berkel, PhD As a specialist in Cardiology, cell biology, and molecular biology, Dr. Theo van Berkel serves as a leading expert at Leiden University. Dr. van Biessen has contributed groundbreaking discoveries to the field of cardiac biomarker use in risk assessment, particularly regarding prognostic value of CCL3, CCL5, and CCL18. He serves as Head of Department at Leiden University's Biopharmaceuticals & Atherosclerosis Center for Drug Research in addition to his contributions at XCelLCure.